Necessary Expansion of the Management Board at Rentschler Biotechnologie
News Nov 08, 2012
The family-owned business based in Laupheim has expanded its management board. As a contract manufacturing organization, Rentschler Biotechnologie GmbH performs research on, develops, and produces biologicals for its international clientele.
Reiner Winkelbauer, who has been the company's Commercial Manager for the past four years, was appointed Managing Director of Finances.
He was previously the Controlling and Chief Financial Officer of AEG in Ulm and later became the Commercial Manager at EADS also in Ulm.
Since September 1, 2012, Thomas Siklosi has strengthened the management board in the GMP Operations area. Before he started working at Rentschler Biotechnologie as manager of the Active Substance Department in 1984, Siklosi worked for Boehringer Mannheim for 10 years. In 2008, he took over the management of GMP Operations at Rentschler.
In the future, Siklosi will also be responsible for the "operational excellence" program at Rentschler that will focus on customer needs and on optimizing quality and efficiency.
Starting from November 1, 2012, he will be actively supported by Luca Dellacroce, the "new face" in Rentschler's management board. In the past, Dellacroce worked for notable companies such as Motorola and Nokia in process optimization.
Frank Ternes will also be a new addition to the management level at Rentschler beginning February 1, 2013.
After 25 years at Boehringer Ingelheim where he last served as Senior Vice President of Biopharmaceutical Contract Manufacturing, Ternes will now become Managing Director of Sales at Rentschler.
Dr. Nikolaus F. Rentschler, CEO and owner, explains the necessary changes that led to a larger management board as follows:
"To accommodate the rapid growth of the company during the past 10 years, the management board had to also "grow." Internal processes must be constantly reconsidered and optimized in order to serve our customers even better and more efficiently. For this reason, I decided to implement the necessary steps to achieve process optimization in my company. I wish Messrs. Winkelbauer, Siklosi, Dellacroce, and Ternes the strength and fortitude, as well as the determination and perseverance to act in the interests and for the success of my company."
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
BC Platforms Announces Collaborations in Multiple Sclerosis ResearchNews
Company's technology and research platforms used to better understand genetic basis of MS.READ MORE
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE